immutep limited (asx:imm; nasdaq:immp) ceo and executive director marc voigt provides company update
Published 3 years ago • 200 plays • Length 4:32
Download video MP4
Download video MP3
Similar videos
-
12:28
immutep (asx:imm, nasdaq:immp) ceo marc voigt provides an update on clinical trials
-
7:13
from the helm: immutep's (asx:imm, nasdaq:immp) executive director & ceo marc voigt
-
7:13
from the helm: immutep's (asx:imm) executive director & ceo marc voigt
-
10:01
immutep limited (asx:imm, nasdaq:immp) encouraging results for immutep's cancer therapies
-
7:43
immutep (asx:imm; nasdaq: immp) company update on start of 2021
-
11:15
amc options scam? the real reason prices aren’t moving - amc stock short squeeze update
-
1:00:05
asx daily rundown | financial results begin with amp, transurban, mirvac, plus myers trading update
-
5:54
how to buy amanah saham malaysia 3 through myasnb and maybank m2u (2024 asm3 tutorial)
-
31:08
immutep (asx:imm) 2023 agm - ceo presentation
-
15:49
immutep (asx:imm) - webinar presentation
-
4:19
immutep (asx:imm) clinical trial update
-
27:17
immutep limited (asx:imm, nasdaq:immp) - fireside chat with immutep limited
-
16:07
immutep (asx:imm) - webinar presentation
-
47:53
immutep (asx:imm, nasdaq:immp) tacti-003 results, june 2024
-
7:43
immutep (asx:imm) company update on start of 2021
-
3:33
immutep (asx:imm) reports positive trial data
-
6:03
immutep (asx:imm, nasdaq:immp) reports positive discussions with the fda and strong survival data
-
16:06
immutep (asx:imm) - webinar presentation
-
6:59
immutep (asx:imm; nasdaq: immp) global leader in development of lag 3 gene immuno-therapies
-
5:42
immutep (asx:imm, nasdaq:immp) receives fast track designation from fda - october 12, 2022
-
4:44
immutep (asx:imm, nasdaq:immp) - innovative cancer therapies
-
6:25
immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
Clip.africa.com - Privacy-policy